课题基金 / 基金详情

SAFETY AND IMMUNOGENICITY OF CANARYPOX CMV (VCP260) IN HEALTHY ADULTS

SAFETY AND IMMUNOGENICITY OF CANARYPOX CMV (VCP260) IN HEALTHY ADULTS
金丝雀痘 CMV (VCP260) 对健康成年人的安全性和免疫原性
批准号:
6219840
负责人:
Stuart E Starr
金额:
$0.06万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

Stuart E Starr的其他基金

相关文献

中文摘要
翻译
筛选了38例患者的合格性。 筛选于1998年3月31日完成。 27例患者已入组并接受了所有4剂疫苗。 十五(15)例患者已完成研究。 5名患者将于1999年4月接受最后一次访视。 4例患者将于1999年6月接受最后一次访视。1例患者在第1次给药后脱落。 1例患者在第2次给药后因重度局部反应退出研究。 1例患者因不符合入选标准而退出研究。未发生与研究疫苗相关的严重不良事件。初步结果表明该疫苗具有免疫原性。
英文摘要
Thirty-eight (38) patients were screened for eligibility. Screening was completed on March 31, 1998. Twenty-seven (27) patients have been enrolled and have received all 4 doses of vaccine. Fifteen(15) patients have completed the study. Five (5) patients will have their final visit in April, 1999. Four (4) patients will have their final visit in June, 1999. One (1) patient dropped out after dose #1. One (1) patient was dropped from the study due to a severe local reaction after dose #2. One (1) patient was dropped from the study for not meeting entrance criteria. There have been no serious adverse events related to study vaccine. Preliminary results indicate that the vaccine were immunogenic.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG377--ANTIRETROVIRAL REGIMENS W/ COMBOS OF PROTEASE INHIBITORS
  • 批准号:
    6595455
  • 项目类别:
  • 资助金额:
    $18.67万
  • 财政年份:
    2002
  • 负责人:
    Stuart E Starr
  • 依托单位:
ACTG377--ANTIRETROVIRAL REGIMENS W/ COMBOS OF PROTEASE INHIBITORS
  • 批准号:
    6306322
  • 项目类别:
  • 资助金额:
    $0.06万
  • 财政年份:
    1999
  • 负责人:
    Stuart E Starr
  • 依托单位:
ACTG185--USE OF HIVIG FOR PREVENTION OF MATERNAL/FETAL TRANSMISSION OF HIV
  • 批准号:
    6116874
  • 项目类别:
  • 资助金额:
    $2.47万
  • 财政年份:
    1998
  • 负责人:
    Stuart E Starr
  • 依托单位:
ACTG 265--LIVE ATTENTUATED VARICELLA VACCINE IN HIV INFECTION CHILDREN
  • 批准号:
    6116899
  • 项目类别:
  • 资助金额:
    $2.47万
  • 财政年份:
    1998
  • 负责人:
    Stuart E Starr
  • 依托单位: